Orthobiologics maker Bioventus postponed its initial public offering which was slated to raise up to $150 million for the company, according to Renaissance Capital. The company plans to float 8.8 million shares at a price range of between $16 and $18, and plans to list on the NASDAQ Global Market under the ticker “BIOV”. The initial […]
Regenerative Medicine
Derma Sciences acquires BioD for $21.3m
Derma Sciences (NSDQ:DSCI) said today it is buying regenerative medicine developer BioD for $21.3 million up front, with the possibility of an additional $56.5 million. The deal between Princeton, N.J.-based Derma Sciences and Cordova, Tenn.-based BioD includes regulatory milestone payments up to $30 million and earn outs based on net sales growth of up to $26.5 million. “The acquisition of […]
Orthofix touts high fusion rates in Trinity Evolution study
Orthofix (NSDQ:OFIX) today announced the publication of a 12-month study which examined the use of its Trinity Evolution cellular bone allograft in patients undergoing vertebral fusions, touting a greater than 90% fusion rate at 12 months The study was published in the European Spine Journal, Lewisville, Texas-based Orthofix said. “We are committed to investing in meaningful […]
Xtant Medical expands Belgrade tissue processing facility
Xtant Medical said today it is expanding its Belgrade, Mont. tissue processing facility to include 7 new processing rooms. The company said the addition will more than double it’s capacity of processing rooms which are available for production. “These facilities allow for increased processing volume of our high-demand products and reduces the time required to get […]
Tissue Regenix CE Mark expected 6 months early
Tissue Regenix said today it expects to pick up CE Mark approval in the European Union for its OrthoPure XT and XM procine tendon and meniscus products approximately 6 months ahead of schedule. Clinical trials are currently underway for both products, the company said, and positive clinical data from the trials has resulted in an […]
Bioventus files for $150m IPO
Orthobiologics maker Bioventus yesterday registered for an initial public offering it plans to use to pay off debt. Durham, N.C.-based Bioventus was formed in 2012 when Smith & Nephew (NYSE:SNN) spun out its biologics and clinical therapies division in a joint venture with venture capital firm Essex Woodlands. In October 2014 Bioventus acquired the OsteoAMP product line from Advanced […]
Biostage files for orphan drug designation for Cellspan artificial esophagus
Organ regeneration specialist Biostage (NSDQ:BSTG) said it asked the FDA for orphan drug status for its Cellspan artificial esophagus. If the request is granted, Holliston, Mass.-based Biostage, formerly know as Harvard Apparatus Regenerative Technology, would win 7 years of market exclusivity after FDA approval, plus tax credits and an exemption from the federal safety watchdog’s drug registration […]
Avita taps IMS for BARDA economics study of ReCell
Avita Medical (ASX:AVH) said today it tapped health economics group IMS Health to join in an study of its ReCell regenerative medical device to evaluate its economic benefits when used at U.S. burn centers. The ReCell device is designed to use the patient’s own skin cells to treat a variety of skin issues, including burns, […]
HHS adds $8m, reups contract with Avita Medical
Avita Medical (ASX:AVH) said yesterday that the U.S. Department of Health and Human Services extended its contract with the company to the tune of an extra $8 million to support the U.S. market approval and launch of its ReCell autologous cell harvesting device. The ReCell device is designed to use the patient’s own skin cells […]
Mayo Clinic study yields potential stem cell treatment for bronchopleural fistulas
A new study from the Mayo Clinic has yielded a possible solution for treating bronchopleural fistulas using stem cells harvested from the patient’s abdominal tissue seeded into bioabsorbable meshes. Bronchopleural fistulas are holes that lead from the large airways in the lungs to the membrane that lines the lungs, often caused by postoperative complications of […]
FDA defends response to late Medtronic Infuse data
The FDA reportedly defended its response to the 5-year delay by Medtronic (NYSE:MDT) in reporting results from an internal study of its controversial Infuse bone growth protein, saying it took no action for the late filing because the data was consistent with earlier results on Infuse. A 2-year internal review of some 3,647 patients implanted with Infuse turned […]